<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ERGOLOID MESYLATES - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for ERGOLOID MESYLATES">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>ERGOLOID MESYLATES</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-direct">Direct Natural</span>
<span class="connection-tag tag-semi-synthetic">Semi-Synthetic</span>
<span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>ERGOLOID MESYLATES</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Ergoloid mesylates interact with multiple endogenous receptor systems including alpha-adrenergic, dopaminergic, and serotonergic receptors. Ergoloid mesylates function through multiple mechanisms including alpha-adrenergic receptor blockade, partial dopaminergic and serotonergic activity, and enhancement of cellular metabolism. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. ERGOLOID MESYLATES works through established physiological pathways to achieve therapeutic effects. ERGOLOID MESYLATES is derived from natural sources. Ergoloid mesylates (also known as dihydroergotoxine mesylate) is a mixture of three dihydrogenated ergot alkaloid derivatives: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. These compounds are semi-synthetic derivatives of naturally occurring ergot alkaloids found in the fungus Claviceps purpurea, which parasitizes rye and other grains. The parent ergot alkaloids have been used historically in traditional medicine for obstetric purposes and other therapeutic applications. The natural ergot alkaloids are chemically modified through hydrogenation to reduce their vasoconstrictor properties while maintaining their beneficial neurotropic effects.</p>

<h3>Structural Analysis</h3> The ergoloid mesylates retain the core ergoline ring structure of the naturally occurring ergot alkaloids and with hydrogenation at specific positions (9,10-dihydro derivatives). This modification maintains structural similarity to the natural compounds while improving their safety profile. The ergoline structure is also related to naturally occurring neurotransmitters and shares functional groups with dopamine, norepinephrine, and serotonin. The compounds maintain the indole ring system found in many natural alkaloids and endogenous compounds like tryptophan and serotonin.

<h3>Biological Mechanism Evaluation</h3> Ergoloid mesylates interact with multiple endogenous receptor systems including alpha-adrenergic, dopaminergic, and serotonergic receptors. They demonstrate partial agonist activity at various receptor subtypes involved in neurotransmission and cerebrovascular regulation. The compounds enhance cellular metabolism and oxygen utilization in neural tissues, supporting natural neuronal function and potentially facilitating endogenous neuroprotective mechanisms.

<h3>Natural System Integration</h3> (Expanded Assessment) The medication targets naturally occurring neurotransmitter receptors and enhances endogenous metabolic processes in neural tissue. It works within evolutionarily conserved neurotransmitter systems and may help restore cerebrovascular homeostasis in age-related cognitive decline. The compounds support natural cellular energy metabolism and may facilitate endogenous repair mechanisms in neural tissue. By improving cerebral circulation and cellular metabolism, they may help maintain natural cognitive function and potentially reduce the need for more invasive interventions in mild cognitive impairment.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Ergoloid mesylates function through multiple mechanisms including alpha-adrenergic receptor blockade, partial dopaminergic and serotonergic activity, and enhancement of cellular metabolism. They improve cerebral blood flow, increase neuronal metabolism, and may enhance neurotransmitter function. The compounds demonstrate neuroprotective properties and may stabilize neuronal membranes while improving oxygen and glucose utilization in brain tissue.</p>

<h3>Clinical Utility</h3> Primary therapeutic application is for symptoms of mild to moderate dementia and age-related cognitive decline. The medication has been used for improving mental capacity, mood, and self-care in elderly patients with cognitive impairment. It has a relatively favorable safety profile compared to many other neurotropic medications and is typically used as a long-term supportive therapy rather than acute intervention.

<h3>Integration Potential</h3> Shows good compatibility with naturopathic approaches to cognitive health, including nutritional support, botanical medicines, and lifestyle interventions. The medication could serve as supportive therapy while implementing comprehensive naturopathic protocols for cognitive wellness. It requires appropriate practitioner knowledge of its mechanisms and potential interactions with other therapeutic modalities.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Ergoloid mesylates is FDA-approved and carries limitations regarding its clinical efficacy claims. The FDA has required manufacturers to demonstrate efficacy for specific cognitive enhancement claims, and its approval status has been somewhat controversial. It remains available as a prescription medication and with restricted labeling regarding cognitive benefits.</p>

<h3>Comparable Medications</h3> Other ergot-derived compounds and neurotropic medications have precedent in various formularies. The natural origin from fungal sources provides some parallel to other naturally-derived medications already accepted in integrative medicine practices.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>ERGOLOID MESYLATES</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox checked">✓</span> Direct natural source</li>

<li><span class="checkbox checked">✓</span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox checked">✓</span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Ergoloid mesylates demonstrates clear natural derivation as semi-synthetic derivatives of ergot alkaloids from Claviceps purpurea fungus. The compounds maintain the essential ergoline structure of the parent natural alkaloids while being chemically modified to improve safety and therapeutic index.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>The ergoline ring structure shows significant similarity to naturally occurring neurotransmitters including serotonin, dopamine, and norepinephrine. The indole ring system is found throughout natural alkaloids and endogenous human compounds. Functional similarity to natural neurotransmitters enables receptor interaction.</p><p><strong>Biological Integration:</strong></p>

<p>The medication integrates with endogenous neurotransmitter systems through interaction with alpha-adrenergic, dopaminergic, and serotonergic receptors. It enhances natural cellular metabolic processes and supports endogenous mechanisms of neuronal function and cerebrovascular regulation.</p><p><strong>Natural System Interface:</strong></p>

<p>Works within naturally occurring neurotransmitter pathways and enhances endogenous metabolic processes in neural tissue. Supports natural cerebrovascular function and may facilitate the body&#x27;s own mechanisms for maintaining cognitive function during aging processes.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Generally well-tolerated with mild side effects. Represents a less invasive approach to supporting cognitive function compared to many pharmaceutical alternatives. Long-term use appears relatively safe with appropriate monitoring.</p><p><strong>Summary of Findings:</strong></p>

<p>ERGOLOID MESYLATES demonstrates significant therapeutic value through integration with natural physiological systems. The medication&#x27;s metabolic effects work through established biological pathways, supporting the body&#x27;s inherent healing processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank Online. &quot;Ergoloid mesylate&quot; DrugBank Accession Number DB01049. University of Alberta. Available at: https://go.drugbank.com/drugs/DB01049. Accessed 2024.</li>

<li>Olin, J., Schneider, L., Novit, A., Luczak, S. &quot;Hydergine for dementia.&quot; Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD000359. DOI: 10.1002/14651858.CD000359.</li>

<li>PubChem. &quot;Dihydroergotoxine mesylate&quot; PubChem CID 44583. National Center for Biotechnology Information. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/44583.</li>

<li>Rehman, H.U. &quot;Ergoloid mesylates (Hydergine) in the treatment of dementia: Current perspectives.&quot; Clinical Interventions in Aging 2008;3(4):615-624.</li>

<li>FDA. &quot;Ergoloid mesylates tablets and oral solution prescribing information.&quot; Multiple manufacturers. Various approval dates with labeling updates through 2020.</li>

<li>Schneider LS, Olin JT. &quot;Overview of clinical trials of hydergine in dementia.&quot; Archives of Neurology 1994;51(8):787-798.</li>

<li>Winblad B, Fioravanti M, Dolezal T, et al. &quot;Therapeutic use of nicergoline.&quot; Clinical Drug Investigation 2008;28(9):533-552.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>